The Proteinuria Paradox: Low Levels Don’t Guarantee Better Kidney Outcomes in Lupus
A longitudinal cohort study published in Arthritis & Rheumatology challenges a common clinical assumption in lupus nephritis (LN). The research followed 239 patients with biopsy-proven LN, comparing those with low-grade baseline proteinuria (less than 1g/24h) to those with higher levels. Contrary to expectations, patients with low-grade proteinuria did not experience better renal outcomes or superior treatment response at 26 and 52 weeks. Both groups had similar risks for significant declines in estimated glomerular filtration rate over a 156-week period. The study also identified glomerulosclerosis as an independent predictor of long-term renal function decline, specifically in patients with relapsing LN.
Why it might matter to you: For cardiologists managing patients with complex comorbidities, this finding underscores that traditional renal risk markers like proteinuria may not fully capture cardiovascular risk in autoimmune conditions. It highlights the critical need for early biopsy and personalized monitoring strategies, which could influence collaborative care pathways with nephrology and rheumatology. Understanding these nuanced predictors is essential for comprehensive risk assessment in patients where cardiovascular and renal diseases intersect.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
